<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8610688</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5937</journal-id>
<journal-id journal-id-type="nlm-ta">Mov Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">Mov. Disord.</journal-id>
<journal-title-group>
<journal-title>Movement disorders : official journal of the Movement Disorder Society</journal-title>
</journal-title-group>
<issn pub-type="ppub">0885-3185</issn>
<issn pub-type="epub">1531-8257</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29389022</article-id>
<article-id pub-id-type="pmc">5889332</article-id>
<article-id pub-id-type="doi">10.1002/mds.27314</article-id>
<article-id pub-id-type="manuscript">NIHMS933342</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Age- and CGG Repeat-Related Slowing of Manual Movement in Fragile X Carriers: A Prodrome of FXTAS?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shickman</surname>
<given-names>Ryan</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Famula</surname>
<given-names>Jessica</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leehey</surname>
<given-names>Maureen</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ferrer</surname>
<given-names>Emilio</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rivera</surname>
<given-names>Susan M.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hessl</surname>
<given-names>David</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>MIND Institute, University of California Davis Medical Center, Sacramento, CA, USA</aff>
<aff id="A2">
<label>2</label>Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA</aff>
<aff id="A3">
<label>3</label>Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Davis, CA, USA</aff>
<aff id="A4">
<label>4</label>Department of Psychology, University of California Davis, Davis, CA, USA</aff>
<aff id="A5">
<label>5</label>Center for Mind and Brain, University of California Davis, Davis, CA, USA</aff>
<aff id="A6">
<label>6</label>Department of Neurology, University of Colorado, Denver, CO, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding author: David Hessl, PhD, Professor, Director, Translational Psychophysiology and Assessment Laboratory (T-PAL), MIND Institute, UC Davis Medical Center, 2825 50th Street, Sacramento, CA 95817, Phone: 916-703-0249, <email>drhessl@ucdavis.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>9</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>01</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2019</year>
</pub-date>
<volume>33</volume>
<issue>4</issue>
<fpage>628</fpage>
<lpage>636</lpage>
<!--elocation-id from pubmed: 10.1002/mds.27314-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">Fragile X premutation carriers are at increased risk for fragile X-associated tremor ataxia syndrome (FXTAS), but to date we know little about prediction of onset and rate of progression, and even less about treatment of this neurodegenerative disease. Thus, longitudinal study of carriers, and identification of potential biomarkers and prodromal states, is essential. Here, we present results of baseline assessments from an ongoing longitudinal project.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">The cohort consisted of 73 males, 48 with the fragile X mental retardation 1 (<italic>FMR1</italic>) premutation (55â€“200 cytosine-cytosine-guanine, CGG repeats) and 25 well-matched controls (&lt; 40 repeats) between 40 and 75 years. At enrollment, none met criteria for FXTAS or had any clinically-significant tremor or ataxia by blinded neurological examination. The battery consisted of measures of visual memory, spatial working memory, response inhibition, motor speed and control, planning and problem solving, sustained attention, and a standardized movement disorder evaluation.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">Contrary to expectations, there were no significant differences between premutation carriers and controls on any measure of executive function. However, premutation carriers had significantly longer manual movement and reaction times than controls, and the significant interaction between CGG repeat and age revealed the slowest movement times among older carriers with higher CGG repeat alleles. A subset of premutation carriers had marginally lower scores on the ataxia evaluation, and they performed no differently from controls on the parkinsonism assessment.</p>
</sec>
<sec id="S4">
<title>Conclusion</title>
<p id="P4">Early-developing cerebellar or fronto-motor tract white matter changes, previously documented in MRI studies, may underlie motor slowing that occurs before clinically observable neurological symptoms.</p>
</sec>
</abstract>
<kwd-group>
<kwd>tremor</kwd>
<kwd><italic>FMR1</italic> gene</kwd>
<kwd>neurodegeneration</kwd>
<kwd>ataxia</kwd>
<kwd>CANTAB</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>